Johnson & Johnson price target raised to $170 from $160 at Stifel

Stifel raised the firm’s price target on Johnson & Johnson to $170 from $160 and keeps a Hold rating on the shares. Helped by better-than-expected Q3 Pharmaceutical division performance, both Johnson & Johnson Q3 sales and EPS outperformed Stifel and consensus, the firm notes. And looking ahead, the company’s initial 2025 commentary suggests that business fundamentals are “steady-as-she-goes.” Still, looking at the company’s valuation, Stifel believes shares appear fairly valued.